Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Fuse Medical, Inc. (FZMD)
USD0.03
+0.00 (+0.00%)
US OTC Healthcare Medical - Devices
Address
1565 North Central Expressway 75080
Richardson, TX, US
Richardson, TX, US
CEO
Christopher C. Reeg
Website
fusemedical.com
IPO
1999-05-06
CIK 319016 ISIN US36113U1016
Description
Headquartered in Richardson, Texas, Fuse Medical, Inc. operates as a U.S.-based manufacturer and supplier of medical device implants. Its product portfolio primarily encompasses a wide range of orthopedic implants. This includes specialized internal and external fixation devices for the foot and ankle, as well as plating systems and total joint reconstruction implants designed for upper and lower extremities. Additionally, Fuse Medical provides solutions for soft tissue fixation and augmentation, catering to sports medicine procedures. The company's offerings extend to comprehensive spinal implants, addressing indications such as trauma, degenerative disc disease, and various deformities. Beyond its orthopedic line, the company also supplies osteo-biologics and regenerative products. These encompass a variety of materials such as human allografts, tendons, synthetic skin, bone substitutes, and other regenerative tissues. Fuse Medical's client base includes hospitals, diverse medical facilities, and a network of sub-distributors.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.03
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6.3K
Beta
-0.52
Float Shares
10.57M
Free Float %
14.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -25.00% | -57.14% | +50.00% | -50.00% | -80.00% | -78.57% | -80.00% | -99.88% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.03
DCF (Unlevered)
0.16
+437.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Quality scores
Altman Z-Score
1.53
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
4 / 10
Developing
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%-33.4% Q2'23: +7.0% (vs Q2'22)
-
EPS growth Medical - Devices: +28.5%-64.9% Q2'23: +184.8% (vs Q2'22)
-
FCF margin FCF growth · Medical - Devices: +30.9%-2.0% Q2'23: -2.0% (vs Q2'22)
-
EBIT margin Medical - Devices: +6.2%+6.7% ★ Q2'23: +7.4% (vs Q2'22)
-
ROIC Medical - Devices: +3.3%+8.1% ★ Q2'23: +83.0% (vs Q2'22)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q2'23: +0.0% (vs Q2'22)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×2.52× Q2'23: 1.38× (vs Q2'22)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
117.0K
OE per share TTM
0.00
Owner's Yield
5.54%
Maintenance CapEx ratio
32.33%
Maint CapEx / Avg PPE
0.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
5
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Twelve Global, LLC | 1.21M | 30.10% | 1.21M | — | 1.21M | 10.00 | HC, OO | Nevada | 2014-06-09 | ↗ |
| 2 | CCEP Holdings, LLC | 648.0K | 16.20% | 648.0K | — | 648.0K | 10.00 | HC, OO | Texas | 2014-06-06 | ↗ |
| 3 | Axis Global, LLC | 540.0K | 13.50% | 540.0K | — | 540.0K | 10.00 | HC, OO | Nevada | 2014-06-06 | ↗ |
| 4 | ReSurge Hospitals, Inc. | 540.0K | 13.50% | 540.0K | — | 540.0K | 10.00 | HC, CO | Utah | 2014-06-06 | ↗ |
| 5 | BAULCH T | 250.5K | 7.02% | 167.6K | 82.8K | 167.6K | 82.8K | IN | USA | 2012-01-06 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
3.00
Bullish
Ratio by volume
1.67
Bullish
Buys
3
Sells
1
Shares acquired
1,000.0K
Shares disposed
600.0K
Cash buys
—
Cash sales
—
Net activity
+399,999
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-15 | Yellin Lawrence Scott | Officer | A-Award | A | Common Stock | 333,333 | 0.15 | 50.0K | 333,333 | — | ↗ |
| 2022-12-15 | Reeg Christopher C | Officer | A-Award | A | Common Stock | 333,333 | 0.15 | 50.0K | 882,586 | — | ↗ |
| 2022-12-15 | Brooks Mark W | Officer | A-Award | A | Common Stock | 333,333 | 0.15 | 50.0K | 882,586 | — | ↗ |
| 2022-11-16 | Brooks Mark W | Officer | G-Gift | D | Restricted Stock | 600,000 | 0.00 | — | 54,020,130 | — | ↗ |
| 2022-05-25 | Yellin Lawrence Scott | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-31 | Reeg Christopher C | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 6,611,613 | — | ↗ |
| 2021-12-31 | Brooks Mark W | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-12-13 | Reeg Christopher C | Director / Officer / 10% Owner | A-Award | A | Common Stock | 222,223 | 0.45 | 100.0K | 475,723 | — | ↗ |
| 2018-12-13 | McLaughlin William E III | Director / Officer | A-Award | A | Common Stock | 222,223 | 0.45 | 100.0K | 475,723 | — | ↗ |
| 2018-12-13 | Kalra Ricky Raj S. | Director | A-Award | A | Common Stock | 222,223 | 0.45 | 100.0K | 1,475,723 | — | ↗ |
| 2018-12-13 | Brooks Mark W | Director / Officer / 10% Owner | A-Award | A | Common Stock | 222,223 | 0.45 | 100.0K | 475,723 | — | ↗ |
| 2018-12-13 | Bosita Renato V. Jr. | Director | A-Award | A | Common Stock | 222,223 | 0.45 | 100.0K | 1,475,723 | — | ↗ |
| 2018-10-04 | Reeg Medical Industries, Inc. | 10% Owner | P-Purchase | A | Common Stock | 72,139 | 0.68 | 49.1K | 6,611,613 | — | ↗ |
| 2018-10-04 | Reeg Christopher C | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 72,139 | 0.68 | 49.1K | 6,611,613 | — | ↗ |
| 2018-08-01 | Reeg Medical Industries, Inc. | 10% Owner | P-Purchase | A | Common Stock | 2,607,701 | 0.76 | 1.98M | 6,607,701 | — | ↗ |
| 2018-08-01 | Reeg Christopher C | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 2,607,701 | 0.76 | 1.98M | 6,607,701 | — | ↗ |
| 2017-12-29 | Brooks Mark W | Director / 10% Owner | P-Purchase | A | Common Stock | 50,000,000 | 0.20 | 10.00M | 55,000,000 | — | ↗ |
| 2017-12-14 | Reeg Christopher C | Director / Officer / 10% Owner | A-Award | A | Common Stock | 188,500 | 0.20 | 37.7K | 253,500 | — | ↗ |
| 2017-12-14 | McLaughlin William E III | Director / Officer | A-Award | A | Common Stock | 188,500 | 0.20 | 37.7K | 253,500 | — | ↗ |
| 2017-12-14 | Kalra Ricky Raj S. | Director | A-Award | A | Common Stock | 188,500 | 0.20 | 37.7K | 1,253,500 | — | ↗ |
| 2017-12-14 | Brooks Mark W | Director / 10% Owner | A-Award | A | Common Stock | 188,500 | 0.20 | 37.7K | 253,500 | — | ↗ |
| 2017-12-14 | Bosita Renato V. Jr. | Director | A-Award | A | Common Stock | 188,500 | 0.20 | 37.7K | 1,253,500 | — | ↗ |
| 2017-09-21 | Reeg Christopher C | Director / Officer / 10% Owner | A-Award | A | Common Stock | 65,000 | 0.78 | 50.7K | 4,065,000 | — | ↗ |
| 2017-09-21 | McLaughlin William E III | Director / Officer | A-Award | A | Common Stock | 65,000 | 0.20 | 13.0K | 65,000 | — | ↗ |
| 2017-09-21 | Kalra Ricky Raj S. | Director | A-Award | A | Common Stock | 65,000 | 0.78 | 50.7K | 65,000 | — | ↗ |
| 2017-09-21 | Brooks Mark W | Director / 10% Owner | A-Award | A | Common Stock | 65,000 | 0.20 | 13.0K | 5,065,000 | — | ↗ |
| 2017-09-21 | Bosita Renato V. Jr. | Director | A-Award | A | Common Stock | 65,000 | 0.20 | 13.0K | 65,000 | — | ↗ |
| 2017-08-01 | Bosita Renato V. Jr. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-07-13 | Kalra Ricky Raj S. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-01-16 | Reeg Medical Industries, Inc. | 10% Owner | — | D | Amended and Restated Promissory Note | 650,000 | 0.08 | 52.0K | 0 | — | ↗ |
| 2017-01-16 | Reeg Christopher C | Director / Officer / 10% Owner | — | I | Amended and Restated Promissory Note | 650,000 | 0.08 | 52.0K | 0 | — | ↗ |
| 2017-01-16 | NC 143 Family Holdings, LP | 10% Owner | — | D | Promissory Note | 640,239 | 0.08 | 51.2K | 0 | — | ↗ |
| 2017-01-16 | Medtech Family Trust | 10% Owner | — | I | Promissory Note | 640,239 | 0.08 | 51.2K | 0 | — | ↗ |
| 2017-01-16 | Brooks Mark W | 10% Owner | — | I | Amended and Restated Promissory Note | 656,678 | 0.08 | 52.5K | 0 | — | ↗ |
| 2016-12-29 | NC 143 Family Holdings, LP | 10% Owner | P-Purchase | A | Common Stock | 50,000,000 | 0.20 | 10.00M | 55,000,000 | — | ↗ |
| 2016-12-19 | Reeg Medical Industries, Inc. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,000,000 | — | ↗ |
| 2016-12-19 | Reeg Christopher C | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 4,000,000 | — | ↗ |
| 2016-12-19 | NC 143 Family Holdings, LP | 10% Owner | P-Purchase | A | Common Stock | 5,000,000 | 0.08 | 400.0K | 5,000,000 | — | ↗ |
| 2016-12-19 | Medtech Family Trust | 10% Owner | P-Purchase | A | Common Stock | 5,000,000 | 0.08 | 400.0K | 5,000,000 | — | ↗ |
| 2016-12-19 | McLaughlin William E III | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-12-19 | Brooks Mark W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 5,000,000 | 0.08 | 400.0K | 5,000,000 | — | ↗ |
| 2016-12-10 | Shelton Rusty | — | A-Award | A | Stock Options (Right to Buy) | 50,000 | 0.11 | 5.5K | 50,000 | — | ↗ |
| 2016-12-10 | Pratt Chris | — | A-Award | A | Stock Options (Right to Buy) | 300,000 | 0.11 | 33.0K | 300,000 | — | ↗ |
| 2016-12-10 | Dei Randall | — | A-Award | A | Stock Options (Right to Buy) | 50,000 | 0.11 | 5.5K | 50,000 | — | ↗ |
| 2016-12-10 | DONEHEW ROBERT H | — | A-Award | A | Stock Options (Right to Buy) | 300,000 | 0.11 | 33.0K | 300,000 | — | ↗ |
| 2015-12-31 | DONEHEW ROBERT H | — | — | I | Common Stock | 0 | 0.00 | — | 4,660 | — | ↗ |
| 2015-08-27 | Pratt Chris | — | A-Award | A | Common Stock | 450,000 | 0.00 | — | 450,000 | — | ↗ |
| 2015-08-27 | Hexter David | — | A-Award | A | Common Stock | 150,000 | 0.00 | — | 160,461 | — | ↗ |
| 2014-12-15 | Meeker D Alan | — | P-Purchase | A | Common Stock | 100 | 1.25 | 125.00 | 542,200 | — | ↗ |
| 2014-12-12 | Meeker D Alan | — | P-Purchase | A | Common Stock | 100 | 1.25 | 125.00 | 542,100 | — | ↗ |
| 2014-12-11 | Meeker D Alan | — | P-Purchase | A | Common Stock | 1,000 | 1.25 | 1.3K | 542,000 | — | ↗ |
| 2014-12-10 | Meeker D Alan | — | P-Purchase | A | Common Stock | 248 | 1.44 | 357.12 | 541,000 | — | ↗ |
| 2014-05-28 | Shelton Rusty | — | — | I | Common Stock | 0 | 0.00 | — | 540,000 | — | ↗ |
| 2014-05-28 | Pratt Chris | — | — | I | Common Stock | 0 | 0.00 | — | 648,000 | — | ↗ |
| 2014-05-28 | Meeker D Alan | — | — | I | Common Stock | 0 | 0.00 | — | 540,000 | — | ↗ |
| 2014-05-28 | Hexter David | — | — | D | Common Stock | 0 | 0.00 | — | 10,461 | — | ↗ |
| 2014-05-28 | Dei Randall | — | — | I | Common Stock | 0 | 0.00 | — | 180,000 | — | ↗ |
| 2014-05-28 | Brown Jonathan G | — | — | I | Common Stock | 0 | 0.00 | — | 1,206,000 | — | ↗ |
| 2013-07-24 | DONEHEW ROBERT H | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,050,000 | 0.05 | 52.5K | 1,506,428 | — | ↗ |
| 2010-12-16 | NAGELBERG DAVID S | 10% Owner | J-Other | D | Common Stock | 160,000 | 0.08 | 12.0K | 120,000 | — | ↗ |
| 2010-12-15 | NAGELBERG DAVID S | 10% Owner | J-Other | D | Common Stock | 79,229 | 0.06 | 4.8K | 350,000 | — | ↗ |
| 2010-09-27 | DONEHEW ROBERT H | Director / Officer / 10% Owner | X-InTheMoney | D | Stock Option | 120,000 | 0.33 | 39.6K | 215,000 | — | ↗ |
| 2010-07-10 | DONEHEW ROBERT H | Director / Officer / 10% Owner | A-Award | A | Stock Option | 120,000 | 0.33 | 39.6K | 335,000 | — | ↗ |
| 2008-08-07 | DONEHEW ROBERT H | Director / Officer / 10% Owner | A-Award | A | Stock Option | 20,000 | 0.76 | 15.2K | 215,000 | — | ↗ |
| 2007-07-23 | DONEHEW ROBERT H | Director / Officer / 10% Owner | A-Award | A | Stock Option | 30,000 | 0.83 | 24.9K | 195,000 | — | ↗ |
| 2006-07-17 | DONEHEW ROBERT H | Director / Officer / 10% Owner | A-Award | A | Stock Option | 60,000 | 0.60 | 36.0K | 165,000 | — | ↗ |
| 2005-08-26 | DONEHEW ROBERT H | Director / Officer / 10% Owner | A-Award | A | Stock Option | 10,000 | 0.60 | 6.0K | 105,000 | — | ↗ |
| 2004-07-29 | DONEHEW ROBERT H | Director / Officer / 10% Owner | A-Award | A | Stock Option | 95,000 | 0.68 | 64.6K | 95,000 | — | ↗ |
| 2003-07-29 | NAGELBERG DAVID S | 10% Owner | J-Other | A | Common Stock | 429,229 | 0.00 | — | 429,229 | — | ↗ |
| 2003-05-13 | CHAROS ANTHONY | Director | A-Award | A | Common Stock | 10,000 | 0.52 | 5.2K | 10,000 | — | ↗ |
| 2003-03-14 | MCCARTHY JOHN F III | Director / Officer | A-Award | A | Option to purchase common stock | 10,000 | 0.50 | 5.0K | 10,000 | — | ↗ |
| 2003-03-14 | DONEHEW ROBERT H | Director / Officer | A-Award | A | Option to purchase common stock | 10,000 | 0.50 | 5.0K | 10,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
23.3K
Shares Outstanding
73.90M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2022 | Mark W. Brooks President | 550.0K | — | 50.0K | — | — | 221.0K | 821.0K | 6.09% | ↗ |
| 2 | 2022 | Christopher C. Reeg Chief Executive Officer | 285.0K | — | 50.0K | — | — | 19.7K | 354.7K | 14.10% | ↗ |
| 3 | 2022 | Lawrence S. Yellin Chief Financial Officer | 200.0K | — | 50.0K | — | — | — | 250.0K | 20.00% | ↗ |
| 4 | 2021 | Mark W. Brooks President | 550.0K | — | 50.0K | — | — | 841.4K | 1.44M | 3.47% | ↗ |
| 5 | 2021 | Christopher C. Reeg Chief Executive Officer | 285.0K | — | 50.0K | — | — | 229.3K | 564.3K | 8.86% | ↗ |
| 6 | 2021 | Lawrence S. Yellin Chief Financial Officer | 200.0K | — | — | — | — | — | 200.0K | 0.00% | ↗ |
| 7 | 2021 | William E. McLaughlin III Chief Financial Officer | 190.0K | — | — | — | — | 9.5K | 199.5K | 0.00% | ↗ |
| 8 | 2020 | Mark W. Brooks President | 540.9K | — | — | — | — | 1.33M | 1.87M | 0.00% | ↗ |
| 9 | 2020 | Christopher C. Reeg Chief Executive Officer | 264.2K | — | — | — | — | 235.1K | 499.3K | 0.00% | ↗ |
| 10 | 2020 | William E. McLaughlin III Chief Financial Officer | 176.2K | — | — | — | — | — | 176.2K | 0.00% | ↗ |
| 11 | 2019 | Mark W. Brooks President | 682.7K | — | — | — | — | 632.2K | 1.31M | 0.00% | ↗ |
| 12 | 2019 | Christopher C. Reeg Chief Executive Officer | 300.0K | — | — | — | — | 2.1K | 302.1K | 0.00% | ↗ |
| 13 | 2019 | William E. McLaughlin III Chief Financial Officer | 200.0K | — | — | — | — | — | 200.0K | 0.00% | ↗ |
| 14 | 2018 | Mark W. Brooks President | 700.0K | — | 100.0K | — | — | 635.0K | 1.44M | 6.97% | ↗ |
| 15 | 2018 | Christopher C. Reeg Chief Executive Officer | 300.0K | — | 100.0K | — | — | 53.1K | 453.1K | 22.07% | ↗ |
| 16 | 2018 | William E. McLaughlin III Chief Financial Officer | 200.0K | — | 100.0K | — | — | — | 300.0K | 33.33% | ↗ |
| 17 | 2017 | Christopher C. Reeg Chief Executive Officer | 240.0K | — | 50.7K | — | — | 32.2K | 322.9K | 15.70% | ↗ |
| 18 | 2017 | William E. McLaughlin III Chief Financial Officer | 161.6K | — | 50.7K | — | — | — | 212.3K | 23.88% | ↗ |
| 19 | 2017 | Mark W. Brooks President | — | — | 50.7K | — | — | 100.8K | 151.5K | 33.46% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mark W. Brooks | Chairman of the Board & President | 771.0K | male |
| Christopher C. Reeg | Chief Executive Officer, Secretary & Director | 304.7K | male |
| Lawrence S. Yellin | Chief Financial Officer, Treasurer & Director | 200.0K | male |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FZMD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
